Deals
Tang Capital files for $75 million SPAC IPO priced at $25 a share
Sponsor Tang Capital Management has signaled non-binding interest in taking $50 million of the offering, about 67% of the deal.
The Carnegie Standard reported on Tang Capital Management on October 7, 2026.
October 7, 2026
Sponsor Tang Capital Management has given a non-binding indication that it would buy $50 million of stock at the offering price, roughly 67% of the deal, and said it plans to take more than half of the shares even if outside demand is strong. Kevin Tang, founder and president of Tang Capital Management and chief executive of Aurinia Pharmaceuticals, is chief executive and chair.
Deals
Sponsor Tang Capital Management has signaled non-binding interest in taking $50 million of the offering, about 67% of the deal.